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ABSTRACT
Objective: The objective of this selective EBM review is to determine which treatment is more
effective between loperamide and racecadotril to treat acute diarrhea in adults.
Study design: Review of three English language primary randomized controlled studies
published from 1999-2005.
Data Sources: First study was a RCT that was double blinded, double placebo, parallel study
group and second and third study was RCT single blinded, comparative parallel group that all
compared efficacy of loperamide and racecadotril. These were all found by using PubMed,
COCHRANE and NCBI.
Outcomes Measured: Each of the studies measured the efficacy of each medication by counting
the number of diarrhea stools until recovery was made. Recovery is defined as having 2
consecutive normal stools or having no stools for more than 12 hrs. The number of days the
patient had diarrhea were also counted.
Results: Overall, these studies were clinically significant where both racecadotril and loperamide
treat acute diarrhea rapidly. It was also observed that loperamide causes more adverse events
such as abdominal distention and constipation when compared to racecadotril.
Conclusions: Racecadotril has been shown to be equally effective as loperamide to treat acute
diarrhea in these three studies. Racecadotril also effectively resolves abdominal symptoms and
causes less constipation than loperamide.
Key Words: Loperamide, Racecadotril, Acute Diarrhea
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INTRODUCTION
Diarrhea occurs when either food or liquids are ingested and pass rapidly and/or in large
quantities through the colon therefore making it hard for the colon to absorb those excess liquids
effectively.4 This will lead to excess fluid in the colon which then leads to the watery bowel
movement known as diarrhea.4 This paper will evaluate three RCT’s in an effort to compare the
efficacy of loperamide and racecadotril against acute diarrhea
Infections of the GI tract can lead to acute diarrhea and remains one of the most common
causes of acute diarrhea worldwide affecting all ages, races, and genders.3 Acute diarrhea
remains the third most common symptom seen in doctor’s offices.3 Although the mortality rate is
not high in this country, there are over 200,000 patients that get hospitalized each year for having
acute diarrhea.5 Inpatient care costs about $2,549 and outpatient care costs about $391 each per
patient.5 Therefore, treating diarrhea in a hospital setting has a large impact on our healthcare
system spending.
A variety of different things cause acute diarrhea including viruses, bacteria, certain
medications, and certain digestive disorders such as irritable bowel syndrome and inflammatory
bowel syndrome.4 At the onset of the diarrhea, it is important to determine if it will self-resolve
or if it needs further medical attention. In about 90% of patients that develop acute diarrhea will
resolve on its own.7 These patients usually respond within five days to rehydration and
antidiarrheal medications and would not need a whole diagnostic evaluation.7 Once acute
diarrhea is present for more than seven days or worsening symptoms develop such as fever,
abdominal pain, or bloody stools, diagnostic studies are usually done.7 These studies include
stool cultures, complete blood counts, and a complete metabolic panel.7 These studies will help
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determine if the patient will need antibiotic therapy, IV fluids and/or stronger antidiarrheal
therapy.7
Loperamide is an effective anti-diarrheal medication which has anti-secretory effects and
increases intestinal transit time.1 Because of the increase transit time, it is known for its side
effects of rebound constipation and abdominal distention.1 Racecadotril is being tested as an antidiarrheal medication because of its anti-secretory properties but at the same time not affecting
the intestinal transit time.1 Comparing the two in studies can show which one is more effective
against acute diarrhea in patients.
OBJECTIVE
The objective of this selective EBM review is to determine which treatment is more
effective between loperamide and racecadotril for the treatment of acute diarrhea.
METHODS
This review consists of three randomized controlled trials that met specific criteria. The
first trial was a RCT that was double blinded, double placebo, parallel group study. The second
and third trials were RCT single blinded, comparative parallel group studies. The populations
used in these trials were adults greater than 18 years old that have been experiencing diarrhea for
at least 24 hrs but for no more than five days. Racecadotril 100 mg was used as the intervention
group and loperamide 2mg was used as the comparison group. The outcomes measured were
counting the number of episodes of diarrhea and the number of days the patient had diarrhea.
Key words used to research for this topic includes loperamide, racecadotril, and acute
diarrhea. All three articles were published in English and published in peer reviewed journals.
All articles were researched by the author using PubMed, COCHRANE and NCBI databases.
These articles were selected based on relevance to my keywords and topic which could then
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answer my POEM question adequately. Inclusion criteria during my search were RCT’s that
were single or double blinded studies published after 1996. Exclusion criteria during my search
were studies that contained patients that were pregnant, under 18 years old and/or had chronic or
infectious diarrhea more than five days. Statistics reported and used were control event rate
(CER), experimental event rate (EER), relative benefit increase (RBI), absolute benefit increase
(ABI), number needed to treat (NNT), confidence interval (CI), p-value, relative risk increase
(RRI), absolute risk increase (ABI), and number needed to harm (NNH).
The demographics and characteristics of the studies used in this review are displayed in Table 1.
Table 1: Demographics of included studies
Study
Prado1
(2002)

Type
RCT=
singleblinded,
comparativ
e, parallel
group

#Pt
945

Vetel2
(1999)

RCT=
doubleblinded,
double
placebo,
parallel
group study

157

Wang3
(2005)

RCT=
singleblinded
parallel
group study

62

Age (yrs)
On
racecadotr
il=
35.9 + 12.
1
On
loperamid
e= 36.4 +
13.5
On
racecadotr
il=
40.9 + 1.8
On
loperamid
e= 41.5 +
2.2

Inclusion criteria
Pt > 18yo, having
acute diarrhea for
at least 24hrs but
no more than 5
days. Pt passed 3
watery stools w/in
the past 24 hrs.

Exclusion criteria
Pt with chronic, dysenteric
bloody, or iatrogenic
diarrhea. Pt with acute UC or
Pseudomembranous colitis
from abx

w/d
0

Interventions
One group given
racecadotril 100 mg
given 3xdaily.
Another group given
loperamide 2mg
given 3xdaily.
Both groups for no
more than 7 days.

Pt > 18yo, having
acute diarrhea for
at least 24hrs but
no more than 5
days

Pt with bloody, purulent, or
chronic diarrhea. Pt w/
functional intestinal disorder.
Pt started new meds 7days
prior or received abx tx 15
days prior to diarrhea. Pt with
renal/hepatic
insufficiency,HIV
positive,DM, or progressive
concomitant infection.

8

On
racecadotr
il=
38.4 + 15.
1
On
loperamid
e= 34.7 +
12.3

Pt > 18yo, having
acute diarrhea for
at least 24hrs but
no more than 5
days. Pt passed 3
watery stools w/in
the past 24 hrs.

Pt with bloody,iatrogenic, or
chronic diarrhea. Pt w/ fxn
intestinal disorder. Pt
received abx tx prior to
diarrhea. Pt with
renal/hepatic dysfunction,
immunocompromised,or
progressive concomitant
infection. Pt tx anti-diarrheal
5 days prior to study.

4

1st dose: one group
given racecadotril 1
capsule (100 mg) and
2 placebo capsules
and other group given
loperamide 2 capsules
(1mg each) and 1
placebo capsule.
Thereafter: one
racecadotril or
loperamide
alternating with
placebo. Both groups
treated for no more
than 7 days
1st group given
racecadotril 100mg
3x daily.
2nd group given
loperamide 2mg 2x
daily.
Both groups treated
for no more than
7days
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Pregnant or lactating

OUTCOMES MEASURED
The basis of all outcomes measured in these studies was targeted towards patient oriented
evidence that would matter to the patient. The primary efficacy criterion in each study was to
count the number of episodes of diarrhea the patient had until recovery or for a maximum of
seven days of treatment. Recovery was defined as having two consecutive normal stools or
having no stools for more than twelve hours. The number of days the patient experienced
diarrhea was also logged into a diary that was given to the patients. Secondary criterion to
evaluating safety of medications involved monitoring and recording adverse events such as
abdominal distension/pain, constipation, and nausea/vomiting.
RESULTS
In the three following RCT studies, the efficacy of loperamide was compared to the
efficacy of racecadotril in the treatment of acute diarrhea. In the Prado study, there were a total
of 945 people with acute diarrhea that participated from 21 different primary care clinics in 14
different countries.1 The duration of diarrhea was monitored starting from the first dose of either
loperamide or racecadotril to when the patient had their first formed stool.1 The duration of
diarrhea in both group population was similar with the median duration being 55 hours.1 The
overall clinical response in both groups had high success rates and the calculations for efficacy
and safety can be seen in Table 2. In 92% of patients that took racecadotril and 93% of patients
that took loperamide had resolution of diarrhea.1 The NNT was calculated to be -100 and is
interpreted as followed: out of 100 patients treated with racecadotril, one less patient would
experience complete resolution of diarrhea. This shows that racecadotril is not more or less
effective than loperamide. Adverse events were also monitored and were seen in 19% of the total
patients.1 Out of this percentage, it was determined that 14.2% of patients on racecadotril and
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23.9% of patients on loperamide had adverse events during the study.1 These adverse events
include patients experiencing constipation, abdominal distention/pain, anorexia, and headaches.
With the exception of headache, the other adverse events were more prominent in the group
taking loperamide. To measure safety of these medications, NNH was calculated and the result
was -10. This would be interpreted as followed: Out of 10 patients treated with racecadotril, one
less would experience adverse effects. This means that there is a reduced risk of developing
adverse effects on racecadotril than if they were treated with loperamide.
Table 2: Loperamide vs. Racecadotril Prado Study1
RBI
ABI
NNT
-0.01
-0.01
-100

RRI
-0.41

ARI
-0.097

CI
95% (50-65) for racecadotril
95% (48-66) for loperamide
NNH
-10

In the Vetal study, there were 157 people with acute diarrhea that participated from 34
different primary care clinics.2 These patients had experienced diarrhea for a mean duration of
39.4 ± 1.7 hours for the racecadotril group and 41.4±2.0 hours for the loperamide group when
they started treatment.2 Before the completion of the study, eight participants withdrew from the
study and the rest were able to follow protocol and complete the study .2 From those that
completed the study, 10 did not complete paperwork correctly and therefore only 147 people
were included in the measurement of efficacy of these medications.2 The mean duration of
diarrhea for both treatments were very similar with 14.9±2.0 hours for racecadotril and 13.7± 2.2
hours for loperamide.2 The overall clinical response in this study was similar to each other with
83.7% for patients on racecadotril and 82.2% for patients on loperamide.2 Results for
calculations of efficacy and safety can be seen in Table 3. The NNT for this study for 67 and is
interpreted as followed: For every 67 patients treated with racecadotril instead of loperamide,
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one additional patient will have complete resolution of symptoms. Adverse events monitored in
this study were the same as in the Prado study with most of the cases being rebound constipation.
In this study, 7.4% of patients taking racecadotril and 12% of patients taking loperamide
experienced adverse events. The NNH was calculated to be -22 which is interpreted as followed:
Out of 22 patients treated with racecadotril, one less would experience adverse effects. Therefore
it is thought here also that by taking racecadotril, it will lessen the chance of experiencing
adverse effects when compared to loperamide.
Table 3: Loperamide vs. Racecadotril Vetal Study2
RBI
ABI
NNT
CI
0.018
0.015
67
95% (79.517-87.883) for
racecadotril
95% (77.612-86.788) for
loperamide
RRI
-0.38

ARI
-0.046

NNH
-22

In the Wang study, there were 62 people with acute diarrhea that participated from 2
primary care clinics and all received at least one dose of treatment.3 Out of these participants,
only 48 patients were considered to follow exact protocol and truly finish the study.3 When
looking at the PP (per protocol) population, the duration of diarrhea were somewhat close at 19
hours in racecadotril group and 13 hours in the loperamide group.3 The results of efficacy and
safety calculations can be found on Table 4. The clinical success rates here were similar to each
other with racecadotril at 95.7% and loperamide at 92.0%. The p-value was 0.3704 which
signifies that it is not statistically significant because there is about a 37% chance the diarrhea
was resolved by chance and not due to the treatments. The NNT was 27 which and can be
interpreted as followed: For every 27 patients treated with racecadotril instead of loperamide,
one additional patient will have complete resolution of diarrhea. Adverse events monitored in
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this study were constipation, bloody stool, skin itching, and abdominal pain upon palpation. The
most significant adverse event was constipation and was mostly seen in the loperamide group
with 29% compared to the racecadotril group at 12.9%.3 The NNH was calculated to be -6 which
is interpreted as followed: Out of 6 patients treated with racecadotril, one less would experience
adverse effects. Therefore it is also agreed here as before that by taking racecadotril, it will
lessen the chance of experiencing adverse effects when compared to loperamide.
Table 4: Loperamide vs. Racecadotril Wang Study3
RBI
ABI
NNT
0.04
0.037
27
RRI
-0.56

ARI
-0.161

p-value
0.3704
NNH
-6

DISCUSSION
The mechanisms of racecadotril and loperamide are different from each other but
ultimately treat acute diarrhea with similarly rapid resolution. Since both mechanisms are
different, this may be the cause of the adverse events seen more in loperamide than racecadotril.
Loperamide acts as an agonist in the µ-opioid receptor in the gut which causes the transit time to
increase allowing the gut to reabsorb more completely and making the stool less watery.1 When
stimulated, these receptors also cause intestinal dilation and decreased peristalsis which could be
related to why these patients experience more abdominal distention and constipation.1 On the
other hand, racecadotril inhibits the enzyme enkephalinase.1 This enzyme inhibits the
enkephalins in the GI tract and therefore increases intestinal antihypersecretory action of the δreceptor agonists.1 Since racecadotril is affecting different receptors, it does not increase
intestinal transit time and therefore causes fewer adverse events as seen in these studies.1
Racecadotril is currently not approved to be used in the United States. In May 2007, the
WHO submitted a proposal to have racecadotril become part of the WHO essential medicine list
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and is still awaiting approval. Even though racecadotril is not approved by the FDA, it has been
approved and widely used in European countries since 1993.6 Recently in October 2012, a brand
name of racecadotril was released named Hidrasec in the UK.8 Currently it costs about 8.42
euros for a pack of 20 tablets which converts to about $10.98 here in the US.8 Loperamide costs
about $9.00 for a pack of 18 tablets. Therefore this shows that both medications are relatively
inexpensive and has equal efficacy.
The MHRA and CHM are responsible for regulating this medication in the UK
Included in the summary of racecadotril characteristics set forth by these agencies are the
following: Racecadotril is currently only known and used to treat acute diarrhea.8 Since there
have not been many studies with this medication, patients with renal or hepatic insufficiency
should use this medication with caution.8 There is no dosage adjustment needed when using this
medication in the elderly population.8 A special warning/precaution on this medication informs
patients that it contains lactose.8 Therefore, patients that are lactose intolerant are warned not to
take this medication.8
CONCLUSION
Racecadotril has been clinically shown to be as equally effective as loperamide in the
treatment of acute diarrhea in these three RCT studies. On the other hand, Loperamide caused
more adverse events in these studies when compared to racecadotril. So even though loperamide
is as effective as racadotril in resolving acute diarrhea, the patient is more at risk of having
adverse events such as constipation, abdominal distention, and nausea/vomiting.
In future studies comparing these medications, larger study groups should be done in
order to get more accurate data. Also, all these studies were performed in Taiwan, France, and
underdeveloped countries in Latin America. Future studies should include study groups in
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different areas of the United States. This could make it possible to develop more data that could
show enough evidence to have this medication approved to treat acute diarrhea here in the
United States.
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